

**Present title and affiliation**

- 1995-present Oncology Consultant  
Hospital Universitario Puerta de Hierro  
Majadahonda, Madrid. Spain
  
- 2004-present Designated Expert  
European Medicines Agency (EMA)
  
- 2011-present Steering Committe  
Grupo Español de Investigación en Sarcomas (GEIS)
  
- 2011-present Steering Comité  
Grupo Español de Tumores Huérfanos e Infrecuentes  
(GETHI)

**Office address**

Clínica Universitaria Puerta de Hierro Majadahonda  
Servicio de Oncología Médica  
Manuel de Falla, 1  
28220 Majadahonda, Madrid

Tel. 911 916 148 / 917 278  
Fax 911 917 278  
[rcubedo@gmail.com](mailto:rcubedo@gmail.com)

**Education& Training**

- 1983-99 Medical Degree  
Universidad Literaria de Valencia  
Valencia. Spain
  
- 1990-94 Medical Oncology Residency  
Hospital 12 de Octubre  
Madrid. Spain
  
- 2004 Visiting fellow  
Sarcoma Unit  
Memorial-Sloan Kettering Hospital  
New York. USA

## Experience / Service

### - Academic Appointments

- |         |  |
|---------|--|
| 1987-89 | Boarder<br>Gastroenterology Department<br>Universidad Literaria de Valencia<br>Valencia. Spain           |
| 1987-89 | Exchange student<br>Mainz Uniklinik - Universitätsmedizin<br>Germany                                     |
| 1995    | Researcher<br>Fondo de Investigaciones Sanitarias (FIS) Grant<br>Hospital 12 de Octubre<br>Madrid. Spain |
| 2011-13 | Tutor of Residents<br>Hospital Universitario Puerta de Hierro<br>Majadahonda, Madrid. Spain              |

### - Other Appointments / Responsibilities

- |              |   |
|--------------|---|
| 1993-94      | Resident's National Representative<br>Medical Oncology National Specialty Commission                                |
| 2000-11      | Scientific advisor & editor<br>El Mundo, El Mundo Salud & elmundosalud.com  |
| 2003-10      | Board of Directors<br>Grupo Español de Investigación en Sarcomas (GEIS)   |
| 2004-present | Sworn Oncology Expert<br>Audiencia Nacional<br>Tribunales Superiores de Justicia de Madrid, Valencia<br>y Andalucía |
| 2010-present | Electronic Sarcoma Update Newsletter<br>Editor of the Spanish Edition   |
| 2010-present | GSK International Standing Payer Panel<br>Adviser for Spanish Area  |

## - Institutional Committee Activities

- 2000-05 Mortality Institutional Comission  
Hospital Universitario Puerta de Hierro  
Majadahonda, Madrid. Spain
- 2005-08 Pharmacy & Drugs Institutional Comisión (Member)  
Hospital Universitario Puerta de Hierro  
Majadahonda, Madrid. Spain
- 2009-present Musculoskeletal Tumors Comitee (President)  
Hospital Universitario Puerta de Hierro  
Majadahonda, Madrid. Spain
- 2010-present Breast Cancer Comitee (Member)  
Hospital Universitario Puerta de Hierro  
Majadahonda, Madrid. Spain

## Publicationlist

### - Communications

Mayordomo JI, Paz-Ares L, Mendiola C, Lianes P, López-Brea M, López E, Cubedo R, et al. ***Malignant Germ-Cell Tumors (MGCT) in women. Long term results in 40 patients.*** Proceedings of the European Society of Medical Oncology Symposium, 1992; Amsterdam.

Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes MP, López-Brea M, López E, Cubedo R, et al. ***Progress Report of a randomized trial on the value of adding G-CSF or GM-CSF to standard antibiotic therapy in the treatment of febrile neutropenia.*** Proceedings of the European Society of Medical Oncology Symposium, 1992; Amsterdam.

Vegh I, Cubedo R, Larrodera L, Montero S, Guzmán C, García I, et al. ***Expression of Growth Factor Receptors (EGFR and IGFR-1) in breast cancer patients.*** Proceedings of the 16th annual San Antonio Breast Cancer Symposium, 1993; San Antonio.

Domínguez-Ortega L, Cubedo-Cervera R. ***Sleep protects against chemotherapy-induced nausea and vomiting.*** 22nd Congress of the International Society of Internal Medicine. Aug. 1994; Budapest.

Mendiola C, García Ribas I, Cubedo R, et al. ***High response rate of taxol in platinum pretreated advanced ovarian cancer.*** 31<sup>st</sup> ASCO Meeting. Los Angeles.

Gomendio B, García E, Pérez-Carrión R, Moyano A, Provencio M, Cubedo R, et al. ***BCRA1 gene alterations in sporadic breast cancer.*** Proceedings of the 7th EORTC Breast Cancer Working Conference, 1996; Bourdeaux. (Abs PP-4-15)

García E, Gomendio B, Pérez-Carrión R, Zamora P, Espinosa E, Provencio M, Cubedo R, et al. **Mutational Study of BCRA1 gene in familial breast cancer.** Proceedings of the 7th EORTC Breast Cancer Working Conference, 1996; Bourdeaux. (Abs PP-4-16)

García E, Gomendio B, Pérez-Carrión R, Moyano A, Provencio M, Cubedo R, et al. **Epidemiology of familial breast cancer, and mutational study of the BCRA1 gene.** Preliminary results. Proceedings of the 21st Meeting of the International Association for Breast Cancer Research, 1996; Paris. (Abs P4-36)

Gomendio B, García E, Zamora P, Espinosa E, Provencio M, Cubedo R, et al. **Frecuence of mutations of the BCRA1 gene in sporadic breast cancer.** Proceedings of the 21st Meeting of the International Association for Breast Cancer Research, 1996; Paris. (Abs P1-3)

Provencio M, Bonilla F, Navarro I, Salas C, Jorge M, Cubedo R, et al. **Survival analysis and prognostic factors in Hodgkin's Disease.** Proceedings of the VI International Conference on Malignant Lymphoma, 1996; Lugano (Abs. 393)

Gil F, Méndez JI, Ruíz A, García J, Trigo M, Cubedo R, et al. **Information in new medical oncology patients: Quality and associated factors.** Proceedings of the 32nd ASCO Meeting, 1996; Philadelphia.

Provencio M, Bonilla F, Navarro F, Jorge M, Cubedo R, España P. **Factors influencing first relapse in Hodgkin's disease.** 21st ESMO Congress, 1996; Vienna.

Provencio M, Bonilla F, Salas C, Navarro F, Cubedo R, España P. **Breast cancer after treatment for Hodgkin's disease.** 21st ESMO Congress, 1996; Vienna.

García E, Gomendio B, Pérez-Carrión R, Zamora P, Espinosa E, Provencio M, Cubedo R, España P, Bonilla F. **Familiarity and BCRA1 gene alterations in breast cancer.** Annals Oncol 96;7(suppl 5): 6

Gil F, Méndez JI, Ruíz A, García J, Trigo M, Cubedo R, et al. **Information in new medical oncology patients: Quality and associated factors.** ASCO Proceedings. J Clinical Oncol 1996;15:507.

Gomendio B, Silva JM, Provencio M, García Patiño E, García JM, Cubedo R, et al. **Presence of germline BCRA2 gene mutations in sporadic breast cancer: clinical correlation.** European Cancer Conference ECCO 9 1997; Hamburg.

Jorge M, España P, Provencio M, Navarro F, Villanueva MJ, Cubedo R, Salas C, Millán I. **Long follow-up of gastric lymphoma.** European Cancer Conference ECCO 9 1997; Hamburg.

Tabernerero J, Paz-Ares L, Cubedo R, et al. **Phase II study of sbcutaneous recombinant interleukin-2 and intravenous vinblastine in advanced renal cell carcinoma.** 34<sup>th</sup> Annual ASCO Meeting. 1998. Los Angeles.

Cubedo R, España P, Provencio M, Jorge M, Sánchez A. **Phase II clinical trial of gemcitabine and ifosfamide in inoperable non-smal cell lung cancer.** 23<sup>rd</sup> ESMO Congress. 1988. Athens.

Provencio M, Villanueva MJ, Navarro F, Cubedo R, Bonilla F, España P. **Hodgkin disease: Survival, outcome and excess mortality.** 23<sup>rd</sup> ESMO Congress. 1988. Athens.

Provencio M, Navarro F, Villanueva MJ, Sánchez A, Cubedo R, Bonilla F. **Phase II clinical trial of a new vinorelbine schedule in metastatic breast carcinoma.** 35<sup>th</sup> Annual ASCO Meeting. 1999. Atlanta.

Provencio M, Navarro F, Villanueva MJ, Sánchez A, Cubedo R, et al. **Phase II clinical trial of a new vinorelbine schedule in metastatic breast carcinoma.** Abstracts Book. 9th International Congress on Anti-Cancer Treatment. 1999. Paris

Provencio M, España P, Salas C, Millán I, Vargas JA, Román F, Sánchez A, Miralles C, Cantos B, Cubedo R, Bonilla F. **Hodgkin's disease at autopsy.** 11th International Congress on Anti-Cancer Treatment. 2001. Paris

Miralles C, Orea M, Provencio M, Sánchez A, Cantos B, Gea T, Cubedo R, Bonilla F, España P. **Ca 125 associated with multiple benign and malignant pathologies.** ECCO 11. The European Cancer Conference. 2001. Lisboa.

López-Pousa A, Martín J, Balaña C, Poveda A, García del Muro J, Maurel J, Cubedo R. **Phase I-II study of a new formulation of non-pegylated liposomal doxorubicin (Doxo GP-Pharm) as first line treatment of older patients with advanced soft-tissue sarcomas : a GEIS study.** CTOS 14<sup>th</sup> Annual Meeting. 2008. London.

Poveda A, Maurel J, Cubedo R, Casado A, Ayuso JR, Fuster D, Martínez-Trufero J, López-Pousa A, Martín J, García del Muro X. **Phase I-II trial of imatinib and low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors, refractory to high-dose imatinib. A GEIS Study.** ASCO Annual Meeting. 2008. Chicago.

L Manso, E Ciruelos, M Codes, J De la Haba, A Galan, J Baena, A Jaen, M Gil, A Murias, I Blancas, E Gonzalez, D Perez, JL Bayo, J Mel, E Garcia-Martinez, R Cubedo, J Salvador. **Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy** Breast Cancer Res. 2011; 13(Suppl 2): P4

L. Manso, E. M. Ciruelos, M. Codes, J. R. De la Haba, A. Galan, J. M. Baena, A. Jaen, M. Gil, A. Murias, I. Blancas, E. Gonzalez, D. Perez, J. L. Bayo, J. R. Mel, E. Garcia-Martinez, R. Cubedo, J. Salvador. **Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER-2 negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first line therapy.** ASCO Annual Meeting 2011 (Abstract #83094)

A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. Y. Blay. **A phase II study of a new formulation of non-pegylated liposomal doxorubicin (Doxorubicin GPPHarm) as first-line treatment in advanced soft-tissue sarcomas patients (STS) aged 65 years or older: A GEIS trial.** ASCO Annual Meeting 2011 (Abstract #84727)

J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubio, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero, **Spanish Group for Sarcoma Research (GEIS). KIT, DOG1, PDGFR and IGFR1 gene expression analyses determine two different subpopulations in kit negative GIST-like (KNGL) patients.** ASCO 2011 (Abstract #79107)

Codes M, Manso L, Ciruelos EM, De la Haba- Rodríguez J, Galan A, Baena J, Jaen A , Gil M, Murias A, Blancas I, Gonzalez E, Perez D, Bayo JL, Mel JR, Garcia-Martinez E, Cubedo R, Salvador J. **Value of circulating epithelial tumor ce 115 and circulating endothelial cells (CTCs/CECs) in patients with HER-2 negative recurrent or metastatic breast cancer treatad with bevacizumab (B) in combination with paclitaxel (P) and gemcitabine (G) as first line therapy (AVALUZTrial).** ASCO 2012 Proceedings, J Clin Oncol 2012; 30 (15): e11535

Marlin Broto J, Lopez-Pousa A, Ramos R, Gronchi A, Casali P, Gutierrez A, Picci P, Ferrari S, Cruz J, Fra PL, Casado A, Cubedo R, Lasso R, Poveda A, De Juan A, Balaña C, Calabuig S, Obrador A, Lopez-Guerrero JA. **CUL4A gen underexpression determines worse prognosis in localized high risk soft tissue sarcoma (STS) patients of limbs or trunk wall.**

ASCO 2012 Proceedings, J Clin Oncol 2012; 30 (15): abstr. 10079

## - Publications

Domínguez-Ortega L, Cubedo-Cervera R, Diaz-Gallego E, Cortés-Funés H. **Protection against chemotherapy-induced emesis with sleep.** Lancet 1994; 343(8908). 1298.

Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, et al. **Improved treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.** J Nat Cancer Inst 1995; 87(11):803-808.

Domínguez-Ortega L, Cubedo-Cervera R, Cortés Funés H, Díaz Gallego E. **Sleep protects against chemotherapy induced emesis.** Cáncer 1996; 77(8): 1566-1570.

García-Patino E, Gomendio B, Leonart M, Silva JM, García JM, Provencio M, Cubedo R, España P, Ramón y Cajal S, Bonilla F. **Loss of heterozygosity in the region including the BCRA1 gene on 17q in colon cancer.** Cancer Genet Cytogenet 1998; 104(2): 119-23.

Cubedo R, España P, Provencio M, Jorge M, Sánchez A. **Phase II clinical trial of gemcitabine and ifosfamide in inoperable non-small cell lung cancer.** Annals Oncol 1998;9 suppl.4:103

Provencio M, Villanueva MJ, Navarro F, Cubedo R, Bonilla F, España P. **Hodgkin´s disease: survival and excess mortality;** Annals Oncol 1998;9 suppl. 4:109

Ramía JM, Alcalde J, Dhimes P, Cubedo R. **Metastasis from Choriocarcinoma of the Mediastinum Producing Acute Apendicitis.** Dig Dis and Sciences 1998;43(2):332-334

Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T. **Cancer antigen 125 associated with multiple benign and malignant pathologies.** Ann Surg Oncol. 2003 Mar;10(2):150-4.

Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E, García M, Casado E, Cubedo R, Gravalos C, Alfaro V, Gómez J, Izquierdo MA, Tabernero J. **Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.** Clin Colorectal Cancer. 2007 May;6(7):522-8

Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balaña C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM. **Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.** J Clin Oncol. 2009 Apr 10;27(11):1893-8.

Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, Martínez-Trufero J, Ramón Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E. **Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.** Cancer. 2010 Aug 1;116(15):3692-701

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E. **Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.** Breast Cancer Res Treat. 2010 Aug;123(1):149-57

Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; **Spanish Society of Medical Oncology. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).** Ann Oncol. 2010 Feb;21(2):195-8.

Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortés J. **Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.** J Clin Oncol. 2010 Feb 20;28(6):960-6

Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez Trufero J, Lopez Pousa A, del Muro XG, Lomeña F, Maurel J, Pons F. **Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.** Q J Nucl Med Mol Imaging 2011;55(6):680-7.

Redondo A, Braña A, Bagué S, López Pousa A, García del Muro X, Bernabé D, Ortiz E, Cubedo R, Valverde C, Cruz J, Martínez V, Varela A, Domínguez R, Barber I, López Martín J, Martín J. **Osteosarcoma del Adulto. Guía de Buena Práctica Clínica. Grupo Español de Investigación en Sarcomas (GEIS).** Clinical & Translational Oncology 2012 (2).

García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM ; **Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.** J Clin Oncol. 2011 Jun 20;29(18):2528-33.

Muñoz AJ, Viñolas N, Cubedo R, Isla D. **SEOM guidelines on thrombosis in cancer patients.** Clin Transl Oncol. 2011 Aug;13(8):592-6

García Del Muro X, Martín J, Maurel J, Cubedo R, Bagué S, de Álava E, Pousa AL, Narváez JA, Ortiz E, Pomés J, Poveda A, Romasanta LP, Tendero O, Viñals JM; **Grupo Español de Investigación en Sarcomas (GEIS). [Soft tissue sarcomas: clinical practice guidelines].** Med Clin (Barc). 2011 Apr 9;136(9):408.e1-8.

Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F. **Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.** Q J Nucl Med Mol Imaging. 2011 Dec;55(6):680-7.

Quintero CB, Cubedo R. **Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.** Anticancer Drugs 2012; 23 suppl S1-2.

Balañá C, Cubedo R (eds). **Imatinib in Gastrointestinal Stromal Tumors (GIST) Therapy**. Anti-Cancer Drugs 2012;23:suppl1


Rojas A, Cubedo R. **Precision of capsule endoscopy in anatomical location of small bowel GIST**. Endoscopy (in press)

#### - Books & Chapters

Carnevali Ruiz D, Cubedo R. **Dolor y analgesia**. En: Carnevali Ruiz D, et al (eds.) Manual de diagnóstico y terapéutica médica. 3ª ed. Madrid 1985.

Cubedo R. **Sarcoma de Partes Blandas y de los Huesos**. Melanoma. En: Oncología Para Estudiantes de Medicina 1ª ed. Aran, Madrid 2012

Firmado en Madrid, a 22 de julio de 2013

A handwritten signature in blue ink, consisting of a large, sweeping oval followed by several smaller, more intricate strokes.